TBTuran Buzgan

Turan Buzgan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Turan Buzgan has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Monitoring of Patients Receiving Immunosuppressive and Biological Agent Treatments for Infectious Complications

    by Ayse Gulden Bekgoz, Rahmet Guner, Orhan Kucuksahin, Imran Hasanoglu, Ayse Kara-Kalem, Bircan Kayaaslan, Turan Buzgan, Mehmet Akin Tasyaran

    Immunosuppressive drugs are increasingly used in the treatment of rheumatologic diseases to achieve disease remission, reduce the frequency of attacks, and prevent relapses. Since the late 1990s, advancements in molecular biology, immunology, and pharmaceutical technologies have led to various new treatment approaches for autoimmune-associated inflammatory diseases.

  • Open Access

    Analysis of Prosthetic Joint Infections, Risk Factors for Treatment Failure and Effect of Teicoplanin in Treatment: A Single-Center, Retrospective, Observational Study

    by Aybegum Ozsahin, Zeliha Kocak Tufan, Rahmet Guner, Turan Buzgan, Osman Tecimel, Mehmet Akin Tasyaran

    With the prolongation of life expectancy and the developments in orthopedic surgery, noteworthy progress has been made in prosthetic joint surgery in recent years. Joint replacement provides pain relief, improves quality of life, and gives independence to individuals. Along with the advances in prosthetic surgery, prosthetic joint infection (PJI) is still the most feared complication of the procedure.


  • Open Access

    A New Laboratory Tool for COVID-19 Severity Prediction, CENIL Score

    by Elif Mukime Saricaoglu, Belgin Coskun, Muge Ayhan, Esragul Akinci, Bircan Kayaaslan, Adalet Aypak, Ayse Yasemin Tezer Tekce, Imran Hasanoglu, Ayse Kaya, Fatma Eser, et al.

    Background/Objectives: Several studies investigated the risk factors for severe COVID-19-related outcomes. Early identification and proper treatment of COVID-19 patients who may develop severe pneumonia are crucial. The aim of this study was to detect the importance of the laboratory parameters for risk prediction of severe pneumonia in COVID-19 patients. Methods: This retrospective cohort study included COVID-19 patients’ laboratory parameters at admission. Biochemical, hematological, coagulation, and inflammatory parameters values were compared between the non-severe and severe groups. Results: A total of 534 COVID-19 patients were screened, and 472 of them were included in this study. The mean age of patients was 64 (±3.1) years; 242 (51.3%) were men. A total of 204 (43.2%) patients were diagnosed as severe cases. The independent predictors of severe illness were C-reactive peptide, Eosinophil, neutrophil–lymphocyte ratio, interleukin-6, and lactate dehydrogenase. These parameters were named as CENIL scores from 0 to 5 points. The findings of this study indicate that these biomarkers identified tend to increase progressively with disease severity in severe COVID-19 patients. Additionally, the CENIL risk score identified a specific cut-off value of 3, highlighting it as a critical threshold for identifying patients at high risk of severe COVID-19 progression. Conclusions: In this study, we identified biomarkers—including CRP, eosinophil count, NLR, IL-6, and LDH—named as CENIL risk score that can help predict the likelihood of severe disease at diagnosis. Clinicians may be more vigilant regarding the development of severe disease in patients with high CENIL risk scores, guided by clinical and radiological findings.


  • Open Access

    Positive effects of health behaviors acquired during the COVID-19 pandemic process on the prevention of other infectious diseases

    by Asi̇yE Çi̇ğDem Şi̇mŞek, Turan Buzgan, Fatma Nur Baran Aksakal, Şuayip Bi̇rİnCi̇, Hülya Şi̇rİn

    Background/aim: It was aimed to evaluate the positive effects of health behaviors (general hygiene, wearing face masks, physical distancing, and travel restrictions) acquired during the coronavirus disease 2019 (COVID-19) pandemic on the prevention of other infectious diseases in Ankara Province, Türkiye. Materials and methods: This study was designed retrospectively. Among the notifiable group A infectious diseases, acute intestinal infections (AIIs) with International Classification of Diseases, Tenth Revision diagnosis codes A09 (diarrhea and gastroenteritis presumed to be of infectious origin), R11 (nausea and vomiting), and K52 (other noninfectious gastroenteritis and colitis) , as well as influenza, tuberculosis, measles, varicella, malaria, and meningococcal meningitis were included in the scope of this study. The data of the selected infectious diseases in Ankara Province for the last 2 years before the pandemic (January 2018-December 2019) and for the 2-year period of the pandemic (January 2020-December 2021) were analyzed after checking the data. The number of cases were presented as frequencies, the 1-sample chi-squared test was used in the statistical analysis and the statistical significance level (α) was taken as 0.05. Results: The findings for each disease/disease group were discussed under separate headings. Comparing the prepandemic period (2018-2019) with the pandemic period (2020-2021), the decreases in the number of cases of selected infectious diseases, except influenza, were statistically significant. Conclusion: Undoubtedly, the experience gained from the pandemic struggle will guide us in shaping our future lives. From this point forward, we should be aware that living in crowded environments and as a highly mobile population, that unhygienic habits are unfavorable for the spread of all infectious diseases, and we should take care to continuously apply the precautions for healthy living in our new lifestyle.


  • Monosit/ Yüksek Dansiteli Lipoprotein (MHR) ve COVID-19 Arasındaki İlişkinin Değerlendirilmesi

    by Belgin Coşkun, Müge Ayhan, Elif Mukime Saricaoğlu, Rahmet Güner, Esragül Akinci, Turan Buzgan, Bircan Kayaaslan, Adalet Aypak, Ayşe Yasemin TEZER TEKÇE, İmran Hasanoğlu, et al.

    Amaç: COVID-19’da şiddetli hastalığı erken tanımak önemlidir. Monosit / yüksek dansiteli lipoprotein oranı (MHR), inflamasyon seyrini belirlemede kullanılan yeni bir belirteçtir. Bu çalışmada MHR ile COVID-19 seyri arasındaki ilişkiyi incelemek amaçlanmıştır. Materyal ve Metod: Laboratuvar ile konfirme edilmiş COVID-19 hastaları retrospektif olarak analiz edildi. Hastanemize başvuran hastanın ilk günki klinik semptomları, bulguları, ve laboratuvar sonuçları hastane bilgi işlem sisteminden taranarak kayıt altına alındı. Çalışmamıza toplam 301 hasta dahil edildi. Hastalar Dünya Sağlık Örgütü (DSÖ) klavuzu dikkate alınarak sınıflandırıldı. MHR hastaların hastaneye kabul edildiği ilk gün bakılan laboratuvar verileri kullanılarak hesaplandı. MHR ile COVID-19 şiddeti arasındaki ilişki değerlendirildi. Hasta verileri SPSS 25 (SPSS Inc., Chicago, IL, USA) kullanılarak analiz edildi. İstatistiksel olarak P<0.05 olan farklılıklar anlamlı kabul edildi. Bulgular: Hastaların 196 (%65,1)’sı hafif ve orta semptomlu COVID-19 iken, 105 (%34,9)’i şiddetli COVID-19 idi. Çalışmamızda şiddetli COVID-19 hastalarında yaş ortalamasının daha yüksek olduğu ve komorbid hastalıkların daha sık görüldüğü bulunmuştur. Çalışmamızda grublar arasında monosit sayısında anlamlı fark izlenmez iken, şiddetli COVID-19 hasta grubunda MHR anlamlı olarak daha yüksek saptanmıştır. Sonuç: COVID-19’da gerçekleşen sitokin fırtınasında monositler önemli rol üstlenir. Gelişen inflamasyon nedeni ile hastalarda dislipidemi izlenir. MHR COVID-19’da inflamatuar biyobelirteç olarak kullanılabilir. Objective: Early diagnosis is important for severe diseases in COVID-19. Monocyte/high dansity lipoprotein ratio (MHR) is a new prognostic marker indicating inflammation. We aimed to investigate the relationship between MHR and diseases severity in COVID-19. Materials and Methods: Patients with laboratory confirmed COVID-19, were retrospectively analyzed. Clinical symptoms, signs and laboratory data on the first day of hospitalization were obtained from medical records of hospital. The clinical data of 301 patients were included in study. Cases were diagnosed on the basis of interim guidance of World Health Organization (WHO). Patients were classified into two groups as non-severe COVID-19 and severe COVID-19. MHR were calculated with laboratory data on the first day of hospitalization. The relationship between MHR level and COVID-19 severity was evaluated. Statistical analysis of the data was performed by using SPSS 25 (SPSS Inc., Chicago, IL, USA) package program. Statistical significance level was accepted as p<0.05. Results: One hundred ninety-six patients (65.1 %) had non-severe COVID-19,105 patients (34.9 %) had severe COVID-19. In our study, it was found that the mean age was higher in severe patients and comorbid diseases were more common. Although monocyte count values were not statistically significantly different, MHR was significantly higher in severe COVID-19 than non-severe COVID-19. Conclusions: Monocytes are very important to cytokine storm in COVID-19. Dyslipidemia can occur in viral infection because of inflammation. MHR can be used as an inflammatory marker in COVID-19.

  • Open Access

    Development and validation of nomogram to predict severe illness requiring intensive care follow up in hospitalized COVID-19 cases

    by Rahmet Guner, Bircan Kayaaslan, Imran Hasanoglu, Adalet Aypak, Hurrem Bodur, Ihsan Ates, Esragul Akinci, Deniz Erdem, Fatma Eser, Seval Izdes, et al.

    Background: Early identification of severe COVID-19 patients who will need intensive care unit (ICU) follow-up and providing rapid, aggressive supportive care may reduce mortality and provide optimal use of medical resources. We aimed to develop and validate a nomogram to predict severe COVID-19 cases that would need ICU follow-up based on available and accessible patient values.Methods: Patients hospitalized with laboratory-confirmed COVID-19 between March 15, 2020, and June 15, 2020, were enrolled in this retrospective study with 35 variables obtained upon admission considered. Univariate and multivariable logistic regression models were constructed to select potential predictive parameters using 1000 bootstrap samples. Afterward, a nomogram was developed with 5 variables selected from multivariable analysis. The nomogram model was evaluated by Area Under the Curve (AUC) and bias-corrected Harrell's C-index with 95% confidence interval, Hosmer–Lemeshow Goodness-of-fit test, and calibration curve analysis.Results: Out of a total of 1022 patients, 686 cases without missing data were used to construct the nomogram. Of the 686, 104 needed ICU follow-up. The final model includes oxygen saturation, CRP, PCT, LDH, troponin as independent factors for the prediction of need for ICU admission. The model has good predictive power with an AUC of 0.93 (0.902–0.950) and a bias-corrected Harrell's C-index of 0.91 (0.899–0.947). Hosmer–Lemeshow test p-value was 0.826 and the model is well-calibrated (p = 0.1703).Conclusion: We developed a simple, accessible, easy-to-use nomogram with good distinctive power for severe illness requiring ICU follow-up. Clinicians can easily predict the course of COVID-19 and decide the procedure and facility of further follow-up by using clinical and laboratory values of patients available upon admission.